Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
6 participants
OBSERVATIONAL
2007-09-30
2010-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
We hypothesis that:
* Women with premenstrual asthma will show increased indices of airway inflammation in various phases the monthly menstrual cycle.
* In women with premenstrual asthma, a change in serum estradiol/progesterone ratio during the late luteal phase is associated with worsening of airway inflammation, air flow limitation and asthma symptoms.
* The use of oral contraceptives is associated with suppression of the cyclical changes in airway inflammation due to lack of fluctuations in estradiol and progesterone levels.
Recruited subjects will be asked to record asthma symptom scores, morning Peak Expiratory Flow Rate (m-PEFR) and rescue asthma medication (β2-agonist) used daily during the one month screening period to identify women with and without pre-menstrual asthma. Asthmatic women with regular menstrual cycles will be evaluated in their follicular phase (days 5-8) and luteal phase (days 21-24) and women on oral contraceptive pills (OCP) will be evaluated on days 9-12 of their OCP cycle and during the days 25-28, off of OCP consecutively for a 2-month period.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Inflammatory Mediators and microRNA Analysis in Premenstrual Asthma
NCT00837395
The Effect of Asthma on Systemic Inflammation, Oxidative Stress and Cardiovascular Morbidity
NCT00957281
Oral Contraceptives and Asthma Control
NCT00662051
Impact of Adult Asthma
NCT00005564
Neural Mechanisms in Asthma
NCT01155843
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
Women with pre-menstrual asthma (PMA): As defined by a 20% or more fall in PEFR and / or change by 20% or more of daily symptom score.
No interventions assigned to this group
2
Women without pre-menstrual asthma
No interventions assigned to this group
3
Women on oral contraceptives
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Requiring low to moderate dose inhaled corticosteroids for control.
* With Pre-bronchodilator FEV1 ≥50% and ≤90% of predicted normal
* With a positive bronchodilator response
* Non smoker or Ex-smoker (Quit \>1 year ago)
* Regular menstrual cycle (24-35 days cycle)
* With and without OCP use
* Constant dose of asthma maintenance medication for at least 30 days prior to enrolment
Exclusion Criteria
* Severe Asthma (FEV1 \<50% or frequent exacerbations or systemic steroid dependence)
* Negative bronchodilator response
* Current Smoker
* Irregular Menses or postmenopausal
* Positive pregnancy test
* Use of hormonal contraceptives other than monophasic OCPs
* Exacerbation or Respiratory Infection or antibiotic use within the last 30 days
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The University of Texas Medical Branch, Galveston
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Anandhi T Murugan, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Texas
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Texas Medical Branch
Galveston, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
07-256
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.